BioPorto's Future Financial Guidance
BioPorto A/S (CPH:BIOPOR), a leader in in vitro diagnostics, has recently outlined its financial objectives for 2025 and shared its growth vision extending through 2029, targeting advancements in the crucial area of Acute Kidney Injury (AKI) diagnostics.
Revenue Projections for 2025
In its guidance for 2025, BioPorto aims for a total revenue between DKK 45 million and DKK 60 million, representing a significant growth range of 24% to 66% over the prior year. This optimistic outlook hinges on increasing sales of their flagship product, ProNephro AKI (NGAL), particularly in the US market, with the anticipated revenue generation more heavily weighted towards the latter part of the year.
Expected Financial Adjustments
The company anticipates an adjusted EBITDA loss of DKK 75 million to DKK 85 million in 2025. This expected increase from last year's loss of DKK 70.6 million is primarily attributed to higher investments in sales and marketing efforts in the United States, as well as ongoing clinical trials to secure FDA approval for ProNephro AKI regarding adult patients. The proactive expansion and clinical validation efforts are clear indicators of BioPorto's commitment to growth in the AKI diagnostics market.
Vision for 2026 and Beyond
Looking ahead to 2026, BioPorto aspires to achieve total revenue between DKK 80 million and DKK 125 million. The company has set a long-term goal of surpassing DKK 700 million (approximately USD 100 million) in total revenue by 2029. This ambitious target aligns with BioPorto's vision to enhance clinical outcomes through actionable biomarker innovations.
Key Growth Catalysts
BioPorto has identified several key strategies to facilitate this revenue growth:
- Inclusion of kidney damage biomarkers in the KDIGO guidelines, expected in early 2026.
- Strategic partnerships with the remaining major clinical chemistry instrument vendors, aiming for wider access and utilization of ProNephro AKI (NGAL).
- Anticipation of FDA approval for ProNephro AKI (NGAL) for adult use by 2027, which could significantly broaden its market reach.
Commitment to Health Solutions
BioPorto’s dedication lies in transforming healthcare through advanced diagnostic solutions. By focusing on actionable biomarkers, the company works towards improving patient management and clinical decision-making. The company's array of products, underpinned by the NGAL biomarker, aims to aid healthcare professionals in diagnosing Acute Kidney Injury—an extremely serious condition that demands prompt attention.
Currently headquartered in Copenhagen, Denmark, with additional facilities in Boston, MA, USA, BioPorto is committed to enhancing the quality of life globally through innovations in the healthcare sector. The company's continuous commitment to research and the development of cutting-edge diagnostic tools reflects its dedication to tackling unmet medical needs in the healthcare landscape.
Investor Relations
For further inquiries or to receive updates about BioPorto’s ongoing initiatives, announcements, and business insights, potential investors are encouraged to reach out directly. Hanne S. Foss, Head of Investor Relations, can be contacted via email at hsf@bioporto.com or through her direct contact number +45 26368918.
Frequently Asked Questions
What is BioPorto's revenue target for 2025?
BioPorto is targeting a revenue range of DKK 45 million to DKK 60 million for 2025.
What factors are driving BioPorto's expected growth?
Growth will primarily be driven by increased sales of ProNephro AKI (NGAL) in the US market and strategic partnerships with major clinical chemistry vendors.
When does BioPorto expect to achieve EBITDA neutrality?
The company aims for positive cash flow and EBITDA neutrality by the end of 2026 at the earliest.
What is the long-term revenue goal for BioPorto?
BioPorto aspires to exceed DKK 700 million in total revenue by 2029.
How can I get further updates from BioPorto?
Interested individuals can sign up for updates on BioPorto's website or contact investor relations for specific inquiries.
